ClinicalTrials.gg
RecruitingNCT05378308Updated Jun 9, 2022

NOACs Use in AF or VTE (SUNSHINE Registry)

An observational study in Atrial Fibrillation, Venous Thromboembolism and Oral Anticoagulant, sponsored by Henan Provincial People's Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2022-06-09.

Sponsored by Henan Provincial People's Hospital · Observational

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
18th of 121
5,000 · median 500
Started
2022
with 39 others
Observational
121 of 377
48 open now
Primary completion
2027-05
later than 107 of 182 live
Registered
157th of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 18th largest by planned enrollment of the 121 observational ones that give a count, is one of 40 that started in 2022, is one of 121 observational ones, reaches primary completion later than 107 of the 182 other live ones, and was the 157th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional inpatient/outpatient disease registry to assess the utilization of Non-vitamin k antagonist oral anticoagulants (NOACs), and associated outcomes. The SUNSHINE registry will focus on the collection and analysis of observational data in medical records from hospital information system (HIS) to evaluate the outcomes related with these NOACs when applied in extensive patient populations outside of clinical research studies. The registry will also allow for mainly combining the atrial fibrillation (AF) and venous thromboembolism (VTE) databases. In brief, the SUNSHINE registry will provide important information on the outcomes of NOACs in routine practice and gather further information on its safety and effectiveness.

Read the detailed description

The SUNSHINE registry will generate the extensive integrated repository of routine clinical care data for NOACs use in patients for various clinical scenarios (mainly with AF or VTE). It will provide important information on the use of NOACs in routine clinical care and gather further information on its safety and effectiveness. The study will compare the characteristics of patients newly anticoagulated with either VKAs or NOACs, to describe the reasons for discontinuing the previous anticoagulant strategy and/or choosing the newly initiated anticoagulant treatment, and to precisely describe the prescriptions of patients newly initiated with a NOAC agent, the treatment patterns, clinical course and the clinical outcomes related with their use. The registry will be a multicenter-collaborated study led by clinical pharmacists and cooperate with health care providers (eg, cardiologists, internists, electrophysiologists, general practitioners, and so on). Target enrollment will be approximately 5,000 patients. It is expected that enrollment will finish in approximately 5 years. Patients who meet the eligibility criteria will be included. Approval from the Henan Provincial People's Hospital Institutional Review Board will be obtained before starting the survey. Since the sensitive data of each patient will be removed (e.g., by name and identification), and only presented in aggregate; therefore, informed consent is waived for this study. Confidentiality will be ensured in accordance with the Declaration of Helsinki. Data collection will include patients' electronic medical records (include demographics, clinical characteristics, medical management, laboratory measurements and imaging parameters, prescription information), the catigories of treating physicians, local NOAC medical insurance policy and NOACs availability of each institution.

03

Conditions studied

  • Atrial Fibrillation
  • Venous Thromboembolism
  • Oral Anticoagulant
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

NOACs use in patients for various clinical scenarios (mainly with AF or VTE).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically diagnosed with AF (eg, by , Holter monitoring, implanted device, etc) or VTE (initial or recurrent acute VTE)
  • Patients who use OACs therapy (including NOAC or VKA) within the preceding 3 months
  • Patients can be enrolled from both inpatient or outpatient settings

Exclusion criteria

Exclusion Criteria:

  • AF resulting from reversible cause factors (e.g., thyroid disease, postoperative AF)
  • Patients with a diagnosis of valvular AF (valvular AF mainly refers to patients with AF that have either rheumatic valvular disease [predominantly mitral stenosis] or mechanical heart valves)
  • Patients participating in an ongoing clinical trial in AF or VTE
  • Have Multiple anticoagulation indications apart from AF or VTE
  • Patients with incomplete information (illogical data, missing or insufficient data)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Interventions

  • OtherPatients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)

    Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability

06

What researchers measure

Primary outcomes

  1. Profiles of patients with OACs

    Patient's characteristics such as age, gender, weight, BMI, disease status; disease characteristics like co-morbidities (congestive heart failure history, hypertension, diabetes mellitus, stroke/transient ischemic attack)/thromboembolism history, vascular disease history, renal impairment, liver impairment, prior major bleeding), treatment history (previous anticoagulation strategy, duration and indication of previous anticoagulation treatment).

    Time frame: During hospitalization

  2. Patients with AF prescribed with OAC

    Difference in the proportion of patients with AF prescribed with OAC between the appropriate use and the inappropriate use group.

    Time frame: During hospitalization

  3. Patients with VTE prescribed with OAC

    Difference in the proportion of patients with VTE prescribed with OAC between the appropriate use and the inappropriate use group.

    Time frame: During hospitalization

Secondary outcomes

  1. Number of major bleeding events

    Major bleeding will be defined according to International Society of Thrombosis and Hemostasis (ISTH) criteria.

    Time frame: 5 years

  2. Number of adverse cardiac events

    Cardiac events are defined as stroke or non-central nervous system (non-CNS) systemic embolism, myocardial infarction, and cardiovascular death.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for May 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2022
First posted
May 18, 2022
StartActual
Jun 6, 2022
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Jun 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05378308
Lead sponsor
Henan Provincial People's Hospital
Responsible party
Sponsor
First posted
May 18, 2022
Start date
Jun 6, 2022
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 9, 2022

Study contacts

Shujuan Zhao
Contact
49800425@qq.com
0086-13837101436
Shujuan Zhao
study director · Henan Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion